Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Open access

Abstract

BACKGROUND: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients. Aldosterone excess is a risk factor for progression of kidney disease. Hyperkalaemia is a concern with the use of mineralocorticoid receptor antagonists. We aimed to determine whether the renal protective benefits of mineralocorticoid antagonists outweigh the risk of hyperkalaemia associated with this treatment in patients with chronic kidney disease. METHODS: We conducted a meta-analysis investigating renoprotective effects and risk of hyperkalaemia in trials of mineralocorticoid receptor antagonists in chronic kidney disease. Trials were identified from MEDLINE (1966-2014), EMBASE (1947-2014) and the Cochrane Clinical Trials Database. Unpublished summary data were obtained from investigators. We included randomised controlled trials, and the first period of randomised cross over trials lasting ≥4 weeks in adults. RESULTS: Nineteen trials (21 study groups, 1 646 patients) were included. In random effects meta-analysis, addition of mineralocorticoid receptor antagonists to renin angiotensin system inhibition resulted in a reduction from baseline in systolic blood pressure (-5.7 [-9.0, -2.3] mmHg), diastolic blood pressure (-1.7 [-3.4, -0.1] mmHg) and glomerular filtration rate (-3.2 [-5.4, -1.0] mL/min/1.73 m(2)). Mineralocorticoid receptor antagonism reduced weighted mean protein/albumin excretion by 38.7 % but with a threefold higher relative risk of withdrawing from the trial due to hyperkalaemia (3.21, [1.19, 8.71]). Death, cardiovascular events and hard renal end points were not reported in sufficient numbers to analyse. CONCLUSIONS: Mineralocorticoid receptor antagonism reduces blood pressure and urinary protein/albumin excretion with a quantifiable risk of hyperkalaemia above predefined study upper limit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12882-016-0337-0

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flow chart
Fig. 1 Study flow chartCC BY · PubMed Central
Fig. 2 a Change in systolic blood pressure from baseline with addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone. For participant numbers see Table 1. b Effect of the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone on end of treatment renal excretory function. For participant numbers see Table 1. c Percentage change from baseline of any measure of urinary protein/albumin excretion with the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone. For participant numbers see Table 1
Fig. 2 a Change in systolic blood pressure from baseline with addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone. For participant numbers see Table 1. b Effect of the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone on end of treatment renal excretory function. For participant numbers see Table 1. c Percentage change from baseline of any measure of urinary protein/albumin excretion with the addition of MRA to ACE-I and/or ARB compared with ACE-I and/or ARB alone. For participant numbers see Table 1CC BY · PubMed Central
Fig. 3 a Relative risk of developing hyperkalaemia above the predefined study limit with the addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone. For participant numbers see Table 1. b Relative risk of developing hyperkalaemia above the predefined study limit with the addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone based on aetiology of CKD (DM diabetes mellitus) included in trial. For participant numbers see Table 1
Fig. 3 a Relative risk of developing hyperkalaemia above the predefined study limit with the addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone. For participant numbers see Table 1. b Relative risk of developing hyperkalaemia above the predefined study limit with the addition of MRA to ACE-I and/or ARB compared to ACE-I and/or ARB alone based on aetiology of CKD (DM diabetes mellitus) included in trial. For participant numbers see Table 1CC BY · PubMed Central
Fig. 4 Funnel plot (pseudo 95 % confidence limits) demonstrating some evidence of publication bias for SBP (Egger test p = 0.08)
Fig. 4 Funnel plot (pseudo 95 % confidence limits) demonstrating some evidence of publication bias for SBP (Egger test p = 0.08)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Cited by

See all 214

Metadata

Authors
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., van den Meiracker, A. H., Saklayen, M. G., Oveisi, S., Jardine, A. G., Delles, C., Preiss, D. J., & Mark, P. B.
Affiliations
  • British Heart Foundation (GB)
  • Research Center for Advanced Science and Technology, The University of Tokyo (JP)
  • National Center for Global Health and Medicine (JP)
  • University of Copenhagen (DK)
  • University of Birmingham (GB)
  • United States Department of Veterans Affairs (US)
  • Qazvin University of Medical Sciences (IR)
  • University of Oxford (GB)
Corresponding author
Currie, Gemma
Venue
BMC Nephrology
Published
2016-09-08
Volume
17
Issue
1
Pages
127-127
ISSN
1471-2369 (ISSN-L)
OpenAlex
W2510521632
Cited by
214
References
87
Citations by year
2026: 19 · 2025: 23 · 2024: 26 · 2023: 34 · 2022: 26 · 2021: 25 · 2020: 21 · 2019: 16 · 2018: 18 · 2017: 6
FWCI
2.01
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Nephrology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • qums (Qazvin University of Medical Sciences) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Funders
  • Kidney Research UK (252892)
  • Seventh Framework Programme (279277)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
mineralocorticoid receptor antagonists, chronic kidney disease, proteinuria, hyperkalemia, renal protection, renin-angiotensin system blockade, blood pressure reduction, glomerular filtration rate, aldosterone excess, hypertension
MeSH terms
Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Glomerular Filtration Rate, Humans, Hyperkalemia, Patient Dropouts, Proteinuria, Randomized Controlled Trials as Topic, Disease Progression, Risk Assessment, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12882-016-0337-0
The paper
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., van den Meiracker, A. H., Saklayen, M. G., Oveisi, S., Jardine, A. G., Delles, C., Preiss, D. J., & Mark, P. B. (2016). Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology. https://doi.org/10.1186/s12882-016-0337-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.